-
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
11 Mar 2024 11:05 GMT
… . Food and Drug Administration (FDA) for conversion … treatment. Following the 110-week blinded treatment period, treatment with study medication … ARBs), ERAs, or aliskiren. Warnings and Precautions Hepatotoxicity … anticipated future clinical trials will not …
-
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
23 Feb 2024 12:05 GMT
… manufacturing and marketing pharmaceutical products for precision … ARBs), ERAs, or aliskiren. Warnings and Precautions Hepatotoxicity … immediately stop treatment with FILSPARI and seek medical attention. … anticipated future clinical trials will not proceed …
-
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
22 Dec 2023 10:12 GMT
… US Food and Drug Administration (FDA) approval, physicians … in the PROTECT trial.
Treatment Goals
The Kidney … additional antihypertensive medications to maintain blood pressure should be … , Bayer, Chemocentryx, Eledon Pharmaceuticals, Inc., Genentech, Hansa …
-
Relationship Between Hypertension, Antihypertensive Drugs and Sexual Dysfunction in Men and Women: A Literature Review
02 Nov 2023 17:57 GMT
… strategy employed was (“aliskiren” OR “Amlodipine” … including testosterone deficiency, antidepressant drugs, aging, changes … treatment.54
Nebivolol and Lower Erectile Dysfunction
Medications … drugs, statins, diuretics, and antidiabetic drugs have …
-
Kidney enzyme as a new target for treatment of high blood pressure, study reveals
29 Aug 2023 05:33 GMT
… lower blood pressure. However, a recent clinical trial which tested a new drug … countries was direct renin inhibitor (aliskiren), and this was approximately 15 … for development of new blood pressure lowering medications.”
Source /Public Release …
-
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
03 Apr 2024 20:30 GMT
… insights from the HONUS trial, including health-related … (ARBs), ERAs, or aliskiren. Warnings and Precautions Hepatotoxicity: … immediately stop treatment with FILSPARI and seek medical attention. If … with enrollment of clinical trials for rare diseases, …
-
What medications can treat systolic heart failure?
14 Aug 2023 14:08 GMT
… that describes the first treatment or therapy doctors prescribe for a disease … inhibitors alongside a drug called aliskiren, which treats high blood pressure.
ARBs offer … rate and blood pressure.
A 2014 trial found that ARNI medication is better …
-
Human medicines European public assessment report (EPAR): Aqumeldi, Enalapril maleate, Heart Failure, Date of authorisation: 15/11/2023, Status: Authorised
22 May 2023 12:17 GMT
… of potassium in the blood), hypotension (low blood pressure), and postural … combination with aliskiren-containing medicines (used to treat essential hypertension [high blood pressure … be used in combination with medicines containing sacubitril and valsartan ( …
-
Human medicines European public assessment report (EPAR): Aqumeldi, Enalapril maleate, Heart Failure, Date of authorisation: 15/11/2023, Status: Authorised
22 May 2023 12:17 GMT
… of potassium in the blood), hypotension (low blood pressure), and postural … combination with aliskiren-containing medicines (used to treat essential hypertension [high blood pressure … be used in combination with medicines containing sacubitril and valsartan ( …
-
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
03 Apr 2024 20:41 GMT
… insights from the HONUS trial, including health-related … (ARBs), ERAs, or aliskiren.
Warnings and Precautions
Hepatotoxicity: … immediately stop treatment with FILSPARI and seek medical attention. If … with enrollment of clinical trials for rare diseases, …